Clinical Trials Logo

Clinical Trial Summary

Polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis (MF) are chronic Philadelphia negative myeloproliferative neoplasms (MPNs) that are characterized by clonal proliferation of hematopoietic stem cells, intramedullary fibrosis, and splenomegaly. While disease manifestations may vary amongst the spectrum of MPNs, quality of life considerations including fatigue, concentration difficulties, pain, sleep disturbance, and depression are negatively affected in most MPN patients. Inflammation has been suggested to be involved in the development of disease-related symptoms. Specific pro-inflammatory cytokines (e.g., IL-1, IL-6, IL-8, and TNF-α) have been associated with particular patient-reported symptoms, including fatigue, abdominal complaints, microvascular symptoms, and constitutional symptoms. Pharmacologic therapy can positively impact MPN related symptoms, specifically with JAK inhibition, however, these treatments often come with negative side effects (e.g., anemia, thrombocytopenia). Much opportunity remains for improving MPN symptoms (i.e., fatigue, insomnia, loss of muscle mass, and debilitation) and quality of life. Yoga, a gentle form of meditative exercise, has been shown to improve symptom management and quality of life parameters in cancer patients and may be effective in improving MPN-related symptoms. Here we propose a study evaluating the efficacy of an online yoga intervention comparing a yoga group to a wait-list control group for improving symptom burden and quality of life in MPN patients. Secondarily, we plan to evaluate the feasibility of collecting potential biomarkers that are related to MPN disease-related activity, such as fatigue (i.e., cortisol and serum cytokines).


Clinical Trial Description

Participants will be recruited nationally utilizing internet-based strategies, including social media (i.e., Facebook, Twitter), social networking sites, online and email listervs, and by contacting MPN patients that were not included in prior feasibility work but expressed their interest in future work. The research team will provide flyers to recruitment contacts to provide a description of the study. MPN patients that expressed interest in future studies will be contacted via email to be asked of their interest in the current study. A flyer will be provided in the email. Prospective organizations will be contacted via email and/or phone and asked to advertise the study by posting the provided recruitment information (e.g., flyers, blurbs) to social media sites and/or websites, emailing listservs, or displaying flyers at location. National organizations agreeing to advertise for the study will be sent recruitment information (e.g., flyers, blurbs) via email, and local organizations will have the option for hand delivery or email. Interested MPN patients will complete an eligibility screening using a Qualtrics link. The eligibility screening takes 5-10 minutes to complete. If ineligible, the participant will be sent an email notification and will be offered a discounted monthly membership to online yoga streaming (Udaya.com). If eligible, the potential participant will be emailed to schedule a time for an intake appointment. The intake appointment will provide greater details pertaining to the study, review of the consent process, and address participant questions. After completing the intake appointment, the participant will be directed to an informed consent page (individual link using Qualtrics) with details concerning the requirements of the study, as well as potential risks and benefits. There will be a place for the participant to type in their electronic signature, which will constitute their consent to participate in the study. After receipt of the signed consent form, the participant will be mailed a Fitbit. They will be instructed to wear the Fitbit for one week to collect baseline physical activity. After one week of wear, the participant will be directed to a Qualtrics link to complete baseline self-report measures. At this point, the participant will be randomized into either the wait-list control group or the yoga group via a web-based randomization tool. Yoga Group: The intervention will be 12-weeks in duration and will consist of a series of pre-approved online yoga classes. MPN patients will be asked to complete a minimum of 60 minutes per week of yoga practice with encouragement to do more if they can. All Udaya.com videos will include a proper warm-up, cool down, and closing mindfulness activity (i.e., message from yoga therapist, brief meditation, final relaxation). A 12-week yoga prescription utilized in prior feasibility work will be improved and modified for this study. The 12-week yoga prescription was designed to be safe and progressive for this specific population. Modifications to the prescription will be made based on qualitative feedback received from patients that participated in prior feasibility work. During the intervention, all classes will offer alternative poses, modifications, and use of props (i.e., yoga blocks and straps) in the instance poses are difficult for the participant (i.e., painful, irregular, uneven breath) and to ensure safety. In addition to specific instruction regarding form and safety, the yoga therapist will provide descriptions of each video that includes tips and modifications to poses (e.g., set the knee on your yoga mat if this feels more comfortable for you). Additionally, patients will also receive a yoga modifications handout outlining the contraindicated yoga poses with modifications. This handout will include an exercise warning for patients that experience dizziness, lightheadedness or faintness, excessive shortness of breath, chest pain, and that they need to stop the activity and contact their health care professional immediately if these symptoms are experienced. Wait-List Control Group: The control group will be asked to maintain their usual level of activity for 16 weeks before being given access to the yoga intervention. Once study participants in the yoga group have completed all outcome measures up through the 4-week follow-up (week 16), participants in the control group will be allowed to participate in the same online yoga prescription that was provided to the yoga group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03503838
Study type Interventional
Source Arizona State University
Contact
Status Completed
Phase N/A
Start date September 23, 2016
Completion date June 12, 2017

See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases